

# Paul Russo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1191027/publications.pdf>

Version: 2024-02-01

198  
papers

11,810  
citations

53660

45  
h-index

31759

101  
g-index

211  
all docs

211  
docs citations

211  
times ranked

14087  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019, 51, 202-206.	9.4	2,702
2	Epidemiology of Renal Cell Carcinoma. <i>European Urology</i> , 2019, 75, 74-84.	0.9	917
3	Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. <i>Genome Biology</i> , 2016, 17, 231.	3.8	746
4	Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3916-3923.	0.8	316
5	Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2017, 35, 668-680.	0.8	262
6	The role of surgery in the treatment of clinically isolated adrenal metastasis. <i>Cancer</i> , 1998, 82, 389-394.	2.0	251
7	Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer. <i>European Urology</i> , 2016, 69, 646-657.	0.9	249
8	A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder. <i>Cancer</i> , 2008, 113, 2471-2477.	2.0	239
9	Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome-associated Renal Cancer. <i>American Journal of Surgical Pathology</i> , 2014, 38, 627-637.	2.1	223
10	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.	13.5	223
11	Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy. <i>Clinical Cancer Research</i> , 2014, 20, 1955-1964.	3.2	208
12	CKD and the Risk of Incident Cancer. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 2327-2334.	3.0	207
13	A Literature Review of Renal Surgical Anatomy and Surgical Strategies for Partial Nephrectomy. <i>European Urology</i> , 2015, 68, 980-992.	0.9	206
14	Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy. <i>Cancer Cell</i> , 2021, 39, 662-677.e6.	7.7	179
15	Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets. <i>Nature Communications</i> , 2016, 7, 13131.	5.8	140
16	Salvage chemotherapy for patients with germ cell tumors. The memorial sloan-kettering cancer center experience (1979-1989). <i>Cancer</i> , 1991, 67, 1305-1310.	2.0	127
17	TCEB1-mutated renal cell carcinoma: a distinct genomic and morphological subtype. <i>Modern Pathology</i> , 2015, 28, 845-853.	2.9	127
18	Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. <i>Lancet Oncology</i> , The, 2020, 21, 283-293.	5.1	121

#	ARTICLE	IF	CITATIONS
19	The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors. <i>Cancer</i> , 1990, 66, 2476-2481.	2.0	119
20	Chromophobe Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2011, 35, 962-970.	2.1	115
21	High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Early intervention is better tolerated. <i>Cancer</i> , 1992, 69, 550-556.	2.0	105
22	MULTIPLE PRIMARY MALIGNANCIES IN RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 1998, 160, 1255-1259.	0.2	98
23	Orthotopic Urinary Diversion After Cystectomy For Bladder Cancer: Implications For Cancer Control And Patterns Of Disease Recurrence. <i>Journal of Urology</i> , 2003, 169, 177-181.	0.2	97
24	Sarcomatoid-variant Renal Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 454-459.	0.6	91
25	Pathologic findings at the time of nephrectomy for renal mass. <i>Annals of Surgical Oncology</i> , 1997, 4, 570-574.	0.7	90
26	Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma. <i>JCI Insight</i> , 2017, 2, .	2.3	89
27	Cytoreductive Nephrectomy " Patient Selection Is Key. <i>New England Journal of Medicine</i> , 2018, 379, 481-482.	13.9	88
28	Survival rates after resection for localized kidney cancer: 1989 to 2004. <i>Cancer</i> , 2008, 113, 84-96.	2.0	85
29	The role of pelvic lymphadenectomy and radical cystectomy for lymph node positive bladder cancer. The memorial sloan-kettering cancer center experience. <i>Cancer</i> , 1994, 73, 3020-3028.	2.0	84
30	Nephrectomy during operative management of retroperitoneal sarcoma. <i>Annals of Surgical Oncology</i> , 1997, 4, 421-424.	0.7	82
31	Histopathologic and Ultrastructural Correlates of Tumor Growth Suppression by High Energy Shock Waves. <i>Journal of Urology</i> , 1987, 137, 338-341.	0.2	79
32	Bilateral non-familial renal cell carcinoma. <i>Annals of Surgical Oncology</i> , 1998, 5, 548-552.	0.7	77
33	Impact of Histologic Subtype on Cancer-specific Survival in Patients with Renal Cell Carcinoma and Tumor Thrombus. <i>European Urology</i> , 2014, 66, 577-583.	0.9	76
34	Sarcomatoid renal cell carcinoma: biology, natural history and management. <i>Nature Reviews Urology</i> , 2020, 17, 659-678.	1.9	76
35	Management of Small Kidney Cancers in the New Millennium. <i>JAMA Surgery</i> , 2015, 150, 664.	2.2	75
36	An Arterial Based Complexity (ABC) Scoring System to Assess the Morbidity Profile of Partial Nephrectomy. <i>European Urology</i> , 2016, 69, 72-79.	0.9	75

#	ARTICLE	IF	CITATIONS
37	The Medical and Oncological Rationale for Partial Nephrectomy for the Treatment of T1 Renal Cortical Tumors. <i>Urologic Clinics of North America</i> , 2008, 35, 635-643.	0.8	70
38	Partial nephrectomy: The rationale for expanding the indications. <i>Annals of Surgical Oncology</i> , 2002, 9, 680-687.	0.7	64
39	The Type of Urinary Diversion After Radical Cystectomy Significantly Impacts on the Patient's Quality of Life. <i>Annals of Surgical Oncology</i> , 2000, 7, 4-8.	0.7	62
40	Use of DWI in the Differentiation of Renal Cortical Tumors. <i>American Journal of Roentgenology</i> , 2016, 206, 100-105.	1.0	61
41	Analysis of renal cancer cell lines from two major resources enables genomics-guided cell line selection. <i>Nature Communications</i> , 2017, 8, 15165.	5.8	61
42	End Stage and Chronic Kidney Disease: Associations with Renal Cancer. <i>Frontiers in Oncology</i> , 2012, 2, 28.	1.3	56
43	Histological subtype of renal cell carcinoma significantly affects survival in the era of partial nephrectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 259.e1-259.e8.	0.8	56
44	Urinary Diversion After Total Pelvic Exenteration for Rectal Cancer. <i>Annals of Surgical Oncology</i> , 1999, 6, 732-738.	0.7	54
45	Ureteral decompression in advanced nonurologic malignancies. <i>Annals of Surgical Oncology</i> , 1996, 3, 393-399.	0.7	53
46	Multi-modal treatment for metastatic renal cancer: the role of surgery. <i>World Journal of Urology</i> , 2010, 28, 295-301.	1.2	46
47	Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 2910-2919.	3.2	45
48	Cytoreductive Nephrectomy and Nephrectomy/Complete Metastasectomy for Metastatic Renal Cancer. <i>Scientific World Journal, The</i> , 2007, 7, 768-778.	0.8	43
49	Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma. <i>European Urology Focus</i> , 2017, 3, 421-427.	1.6	43
50	Intravenous Mannitol Versus Placebo During Partial Nephrectomy in Patients with Normal Kidney Function: A Double-blind, Clinically-integrated, Randomized Trial. <i>European Urology</i> , 2018, 73, 53-59.	0.9	41
51	Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e678-e688.	0.9	41
52	Long-Term Survival Rates after Resection for Locally Advanced Kidney Cancer: Memorial Sloan Kettering Cancer Center 1989 to 2012 Experience. <i>Journal of Urology</i> , 2015, 193, 1911-1917.	0.2	40
53	Differentiation of Clear Cell Renal Cell Carcinoma From Other Renal Cortical Tumors by Use of a Quantitative Multiparametric MRI Approach. <i>American Journal of Roentgenology</i> , 2017, 208, W85-W91.	1.0	40
54	Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma. <i>European Urology Focus</i> , 2019, 5, 642-649.	1.6	40

#	ARTICLE	IF	CITATIONS
55	The Association between Statin Medication and Progression after Surgery for Localized Renal Cell Carcinoma. <i>Journal of Urology</i> , 2014, 191, 914-919.	0.2	39
56	Complete metastasectomy for renal cell carcinoma: Comparison of five solid organ sites. <i>Journal of Surgical Oncology</i> , 2016, 114, 375-379.	0.8	39
57	Surgical Intervention in Patients with Metastatic Renal Cancer: Metastasectomy and Cytoreductive Nephrectomy. <i>Urologic Clinics of North America</i> , 2008, 35, 679-686.	0.8	38
58	Adult Prostate Sarcoma: The Memorial Sloan Kettering Experience. <i>Urology</i> , 2014, 84, 624-628.	0.5	38
59	Pathological Stage T3a Significantly Increases Disease Recurrence across All Tumor Sizes in Renal Cell Carcinoma. <i>Journal of Urology</i> , 2015, 194, 310-315.	0.2	36
60	The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management. <i>European Urology</i> , 2021, 79, 468-477.	0.9	35
61	New Chronic Kidney Disease and Overall Survival After Nephrectomy for Small Renal Cortical Tumors. <i>Urology</i> , 2015, 86, 1137-1145.	0.5	34
62	Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline Summary. <i>Journal of Oncology Practice</i> , 2017, 13, 276-278.	2.5	34
63	Long-Term Renal Function Recovery following Radical Nephrectomy for Kidney Cancer: Results from a Multicenter Confirmatory Study. <i>Journal of Urology</i> , 2018, 199, 921-926.	0.2	34
64	Clear Cell Renal Cell Carcinoma: Associations Between CT Features and Patient Survival. <i>American Journal of Roentgenology</i> , 2016, 206, 1023-1030.	1.0	33
65	Chromophobe Renal Cell Carcinoma: Results From a Large Single-Institution Series. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 373-379.e4.	0.9	33
66	Partial nephrectomy for renal cancer: Part I. <i>BJU International</i> , 2010, 105, 1206-1220.	1.3	32
67	Impact of a Common Clinical Pathway on Length of Hospital Stay in Patients Undergoing Open and Minimally Invasive Kidney Surgery. <i>Journal of Urology</i> , 2014, 191, 1225-1230.	0.2	32
68	Neoadjuvant Gemcitabine-Cisplatin Plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-invasive Bladder Cancer: A 12-year Experience. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 387-394.	0.9	32
69	Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples. <i>European Urology Focus</i> , 2017, 3, 590-598.	1.6	31
70	Cystic Renal Cell Carcinoma: A Report on Outcomes of Surgery and Active Surveillance in Patients Retrospectively Identified on Pretreatment Imaging. <i>Journal of Urology</i> , 2018, 200, 275-282.	0.2	31
71	Abnormal oxidative metabolism in a quiet genomic background underlies clear cell papillary renal cell carcinoma. <i>ELife</i> , 2019, 8, .	2.8	31
72	Cost Comparison of Open and Robotic Partial Nephrectomy Using a Short Postoperative Pathway. <i>Urology</i> , 2015, 85, 596-604.	0.5	30

#	ARTICLE	IF	CITATIONS
73	Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression. <i>Clinical Cancer Research</i> , 2020, 26, 3629-3640.	3.2	30
74	Positive Urinary Cytology Following a Complete Response to Intravesical Bacillus Calmette-Guerin Therapy: Pattern of Recurrence. <i>Journal of Urology</i> , 1994, 152, 382-387.	0.2	29
75	Localized renal cell carcinoma. <i>Current Treatment Options in Oncology</i> , 2001, 2, 447-455.	1.3	29
76	Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma. <i>European Urology Focus</i> , 2018, 4, 986-994.	1.6	29
77	Mucinous Tubular and Spindle-Cell Carcinoma of the Kidney: Clinical Features, Genomic Profiles, and Treatment Outcomes. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 268-274.e1.	0.9	29
78	Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy: Multi-Institutional Analysis. <i>Journal of Urology</i> , 2015, 194, 304-309.	0.2	28
79	Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course. <i>European Urology Focus</i> , 2021, 7, 381-389.	1.6	28
80	Metastatic Carcinoid Tumor of the Prostate. <i>Journal of Urology</i> , 2002, 167, 2526-2527.	0.2	27
81	Open partial nephrectomy: an essential operation with an expanding role. <i>Current Opinion in Urology</i> , 2007, 17, 309-315.	0.9	27
82	Impact of Synchronous Metastasis Distribution on Cancer Specific Survival in Renal Cell Carcinoma after Radical Nephrectomy with Tumor Thrombectomy. <i>Journal of Urology</i> , 2015, 193, 436-442.	0.2	27
83	Renal cell carcinoma with inferior vena cava involvement: Prognostic effect of tumor thrombus consistency on cancer specific survival. <i>Journal of Surgical Oncology</i> , 2016, 114, 764-768.	0.8	26
84	The effect of delaying nephrectomy on oncologic outcomes in patients with renal tumors greater than 4cm. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 239.e1-239.e8.	0.8	25
85	Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 532.e7-532.e13.	0.8	25
86	The Role of Surgery in the Management of Early-Stage Renal Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2011, 25, 737-752.	0.9	23
87	Long-term mortality in patients with germ cell tumors: Effect of primary cancer site on cause of death. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 26.e9-26.e15.	0.8	23
88	Association between visceral and subcutaneous adiposity and clinicopathological outcomes in non-metastatic clear cell renal cell carcinoma. <i>Canadian Urological Association Journal</i> , 2014, 8, 675.	0.3	22
89	Surgical Treatment of Tumors Involving Kidneys With Fusion Anomalies: A Contemporary Series. <i>Urology</i> , 2016, 98, 97-102.	0.5	22
90	Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy. <i>European Urology</i> , 2022, 81, 570-573.	0.9	22

#	ARTICLE	IF	CITATIONS
91	Partial nephrectomy for renal cancer (part II): the impact of renal ischaemia, patient preparation, surgical approaches, management of complications and utilization. <i>BJU International</i> , 2010, 105, 1494-1507.	1.3	21
92	The difficulty in selecting patients for cytoreductive nephrectomy: An evaluation of previously described predictive models. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 35.e1-35.e5.	0.8	21
93	Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers. <i>Scientific Reports</i> , 2020, 10, 701.	1.6	21
94	The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy. <i>European Urology Oncology</i> , 2020, 3, 47-56.	2.6	20
95	TRPM-2 gene expression in normal rat ventral prostate following castration and exposure to diethylstilbestrol, flutamide, MK-906 (finasteride), and coumarin. <i>Prostate</i> , 1994, 24, 237-243.	1.2	19
96	Partial and Radical Nephrectomy for Unilateral Synchronous Multifocal Renal Cortical Tumors. <i>Urology</i> , 2015, 85, 1404-1410.	0.5	19
97	Estimated glomerular filtration rate, renal scan and volumetric assessment of the kidney before and after partial nephrectomy: a review of the current literature. <i>Minerva Urology and Nephrology</i> , 2017, 69, 539-547.	1.3	19
98	Subcentimeter Pulmonary Nodules are Not Associated with Disease Progression in Patients with Renal Cell Carcinoma. <i>Journal of Urology</i> , 2015, 193, 776-782.	0.2	18
99	Association of an organ transplant-based approach with a dramatic reduction in postoperative complications following radical nephrectomy and tumor thrombectomy in renal cell carcinoma. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1983-1992.	0.5	18
100	Results of laparoscopic pelvic lymphadenectomy in patients at high risk for nodal metastases from prostate cancer. <i>Annals of Surgical Oncology</i> , 1998, 5, 173-180.	0.7	16
101	Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing. <i>European Urology Oncology</i> , 2021, 4, 993-1000.	2.6	16
102	Impact of Recurrent Copy Number Alterations and Cancer Gene Mutations on the Predictive Accuracy of Prognostic Models in Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2014, 192, 24-29.	0.2	15
103	Renal cell carcinoma: A nomogram for the CT imaging-inclusive prediction of indolent, non-clear cell renal cortical tumours. <i>European Journal of Cancer</i> , 2016, 59, 57-64.	1.3	15
104	The Prognostic Impact of a Positive Vascular Margin on pT3 Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2016, 195, 264-269.	0.2	15
105	Impact of intraoperative opioid and adjunct analgesic use on renal cell carcinoma recurrence: role for onco-anaesthesia. <i>British Journal of Anaesthesia</i> , 2020, 125, e402-e404.	1.5	15
106	Urologic complications of major pelvic surgery. , 2000, 18, 216-228.		14
107	Validation of a Postoperative Nomogram Predicting Recurrence in Patients with Conventional Clear Cell Renal Cell Carcinoma. <i>European Urology Focus</i> , 2018, 4, 100-105.	1.6	14
108	Impact of lymph node dissection at the time of radical nephrectomy with tumor thrombectomy on oncological outcomes: Results from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 79.e11-79.e17.	0.8	14

#	ARTICLE	IF	CITATIONS
109	The natural history of large renal masses followed on observation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 362.e17-362.e21.	0.8	14
110	The role of surgery in the treatment of clinically isolated adrenal metastasis. , 1998, 82, 389.		14
111	Papillary renal cell carcinoma: a single institutional study of 199 cases addressing classification, clinicopathologic and molecular features, and treatment outcome. <i>Modern Pathology</i> , 2022, 35, 825-835.	2.9	14
112	Myocutaneous Flaps in Genitourinary Oncology. <i>Journal of Urology</i> , 1994, 151, 920-924.	0.2	13
113	Open Mini-Flank Partial Nephrectomy: An Essential Contemporary Operation. <i>Korean Journal of Urology</i> , 2014, 55, 557.	1.2	13
114	Obstructive sleep apnea and Fuhrman grade in patients with clear cell renal cell carcinoma treated surgically. <i>World Journal of Urology</i> , 2017, 35, 51-56.	1.2	13
115	Surgical intervention in patients with metastatic renal cancer: current status of metastasectomy and cytoreductive nephrectomy. <i>Nature Reviews Urology</i> , 2004, 1, 26-30.	1.4	12
116	Functional preservation in patients with renal cortical tumors: The rationale for partial nephrectomy. <i>Current Urology Reports</i> , 2008, 9, 15-21.	1.0	12
117	Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience. <i>International Scholarly Research Notices</i> , 2014, 2014, 1-6.	0.9	12
118	Partial nephrectomy for renal tumors in solitary kidneys: postoperative renal function dynamics. <i>World Journal of Urology</i> , 2015, 33, 2023-2029.	1.2	12
119	Patterns of surveillance imaging after nephrectomy in the Medicare population. <i>BJU International</i> , 2016, 117, 280-286.	1.3	12
120	Histologic subtype impacts cancer-specific survival in patients with sarcomatoid-variant renal cell carcinoma treated surgically. <i>World Journal of Urology</i> , 2016, 34, 539-544.	1.2	12
121	Utility of prospective pathologic evaluation to inform clinical genetic testing for hereditary leiomyomatosis and renal cell carcinoma. <i>Cancer</i> , 2017, 123, 2452-2458.	2.0	12
122	Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 5595-5606.	3.2	12
123	Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma. <i>Cancer</i> , 2021, 127, 3946-3956.	2.0	12
124	Nephrometry scores and perioperative outcomes following robotic partial nephrectomy. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2017, 43, 1075-1083.	0.7	11
125	Renal function recovery after radical nephroureterectomy for upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2018, 36, 257-263.	1.2	11
126	The prognostic significance of nodal disease burden in patients with lymph node metastases from renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 302.e1-302.e6.	0.8	11



#	ARTICLE	IF	CITATIONS
127	Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas. <i>European Urology Focus</i> , 2022, 8, 1278-1288.	1.6	11
128	Value of Partial Nephrectomy for Renal Cortical Tumors of cT2 or Greater Stage: A Risk-benefit Analysis of Renal Function Preservation Versus Increased Postoperative Morbidity. <i>European Urology Oncology</i> , 2020, 3, 365-371.	2.6	10
129	Open partial nephrectomy. Personal technique and current outcomes. <i>Archivos Espanoles De Urologia</i> , 2011, 64, 571-93.	0.1	10
130	Partial nephrectomy achieves local tumor control and prevents chronic kidney disease. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1745-1751.	1.1	9
131	Neutrophil-Lymphocyte Ratio in Small Renal Masses. <i>ISRN Urology</i> , 2014, 2014, 1-5.	1.5	9
132	The Role of Cytoreductive Nephrectomy for Sarcomatoid Renal Cell Carcinoma: A 29-Year Institutional Experience. <i>Urology</i> , 2020, 136, 169-175.	0.5	9
133	Comparison of Cancer Specific Outcomes following Minimally Invasive and Open Surgical Resection of Early Stage Kidney Cancer from a National Cancer Registry. <i>Journal of Urology</i> , 2020, 203, 1094-1100.	0.2	9
134	Clinicopathologic Features of Renomedullary Interstitial Cell Tumor Presenting as the Main Solid Renal Mass. <i>Urology</i> , 2014, 83, 1104-1106.	0.5	8
135	Influence of renal biopsy results on the management of small kidney cancers in older patients: Results from a population-based cohort. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 604.e1-604.e9.	0.8	8
136	The contemporary role of lymph node dissection in the management of renal cell carcinoma. <i>Therapeutic Advances in Urology</i> , 2018, 10, 335-342.	0.9	8
137	The predictive role of preoperative and postoperative neutrophil-lymphocyte ratio in sarcomatoid renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 916-923.	0.8	8
138	The Effect of Patient and Surgical Characteristics on Renal Function After Partial Nephrectomy. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 191-196.	0.9	7
139	A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma. <i>Cancer Discovery</i> , 2022, 12, 2308-2329.	7.7	7
140	Oncological outcomes of partial nephrectomy for renal carcinoma greater than 4cm. <i>Current Opinion in Urology</i> , 2011, 21, 362-367.	0.9	6
141	Second primary malignancies in renal cortical neoplasms: an updated evaluation from a single institution. <i>World Journal of Urology</i> , 2016, 34, 1667-1672.	1.2	6
142	Importance of wide resection in adult spermatic cord sarcomas: Report on oncologic outcomes at a single institution. <i>Journal of Surgical Oncology</i> , 2018, 117, 1464-1468.	0.8	6
143	The association of renal cell carcinoma with gastrointestinal stromal tumors. <i>Journal of Surgical Oncology</i> , 2018, 117, 1716-1720.	0.8	6
144	Clinicopathologic features associated with survival after cytoreductive nephrectomy for nonclear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 811.e9-811.e16.	0.8	6

#	ARTICLE	IF	CITATIONS
145	Preoperative nomogram predicting 12-year probability of metastatic renal cancer – evaluation in a contemporary cohort. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 853.e1-853.e7.	0.8	6
146	A comparison of oncologic and functional outcomes in patients with pt3a renal cell carcinoma treated with partial and radical nephrectomy. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2021, 47, 777-783.	0.7	6
147	Phase III Trial of Intravenous Mannitol Versus Placebo During Nephron-sparing Surgery: Post Hoc Analysis of 3-yr Outcomes. <i>European Urology Focus</i> , 2019, 5, 977-979.	1.6	5
148	Renal cell carcinoma: Associations between tumor imaging features and epidemiological risk factors. <i>European Journal of Radiology</i> , 2020, 129, 109096.	1.2	5
149	Low yield of surveillance imaging after surgery for T1 kidney cancer. <i>World Journal of Urology</i> , 2016, 34, 949-953.	1.2	4
150	Juxtaglomerular Cell Tumor: A Rare, Curable Cause of Hypertension in a Young Patient. <i>Urology</i> , 2019, 134, 42-44.	0.5	4
151	Upper Tract Urothelial Carcinoma in a Patient With Horseshoe Kidney. <i>Urology</i> , 2020, 142, e20-e24.	0.5	4
152	Partial nephrectomy: The rationale for expanding the indications. , 2002, 9, 680.		4
153	A qualitative framework of non-selection factors for cytoreductive nephrectomy. <i>World Journal of Urology</i> , 2021, 39, 3359-3365.	1.2	3
154	Somatic mutations as preoperative predictors of metastases in patients with localized clear cell renal cell carcinoma – An exploratory analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 791.e17-791.e24.	0.8	3
155	Is laparoscopic partial nephrectomy as effective as open partial nephrectomy in patients with renal cell carcinoma?. <i>Nature Reviews Urology</i> , 2008, 5, 12-13.	1.4	2
156	Editorial Comment. <i>Urology</i> , 2009, 73, 1082.	0.5	2
157	Editorial Comment. <i>Urology</i> , 2009, 73, 1297-1298.	0.5	2
158	Delayed systemic treatment in metastatic renal-cell carcinoma. <i>Lancet Oncology, The</i> , 2016, 17, 1187-1189.	5.1	2
159	Benign and tumor parenchyma metabolomic profiles affect compensatory renal growth in renal cell carcinoma surgical patients. <i>PLoS ONE</i> , 2017, 12, e0180350.	1.1	2
160	The association between modifiable perioperative parameters and renal function after nephrectomy. <i>BJU International</i> , 2022, 129, 380-386.	1.3	2
161	Renal tumours: developing understanding leads to developments in surgical treatment. <i>BJU International</i> , 2006, 97, 9-10.	1.3	1
162	To Clamp or Not To Clamp the Main Renal Artery: The Debate Continues. <i>European Urology</i> , 2014, 66, 720-721.	0.9	1

#	ARTICLE	IF	CITATIONS
163	Reply to Williamson S.R. What is the malignant potential of clear cell papillary renal cell carcinoma? Urol Oncol 2016; 34: 420. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 581-582.	0.8	1
164	Progression from tubulovillous adenoma to high-grade adenocarcinoma in Indiana pouch urinary diversion. Urology Case Reports, 2018, 16, 129-131.	0.1	1
165	Editorial Comment on: Treatment Trends and Long-Term Survival Associated with Cryotherapy and Partial Nephrectomy for Small Renal Masses in the National Cancer Database Using Propensity Score Matching by Kitley et al.(From: Kitley W, Sulek J, Sundaram C, et al. J Endourol 2019;33:408-414; DOI: 10.7843/14rgBT.19001)	1.0	1
166	An evaluation of the role of tumor load in cytoreductive nephrectomy. Canadian Urological Association Journal, 2020, 14, E625-E630.	0.3	1
167	The spinal distribution of metastatic renal cell carcinoma: Support for locoregional rather than arterial hematogenous mode of early bony dissemination. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 196.e9-196.e14.	0.8	1
168	Resource-efficient pooled sequencing expands translational impact in solid tumors. Kidney Cancer Journal: Official Journal of the Kidney Cancer Association, 2021, 19, 18-23.	0.1	1
169	Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma.. Journal of Clinical Oncology, 2014, 32, 395-395.	0.8	1
170	Understanding the genomic underpinnings of metastatic chromophobe renal cell carcinoma.. Journal of Clinical Oncology, 2016, 34, 513-513.	0.8	1
171	RE: LAPAROSCOPIC RADICAL NEPHRECTOMY: CANCER CONTROL FOR RENAL CELL CARCINOMA. Journal of Urology, 2002, 168, 1109-1109.	0.2	0
172	Renal cryoablation: a new treatment in need of careful clinical investigation. Nature Clinical Practice Oncology, 2006, 3, 286-287.	4.3	0
173	Editorial Comment. Urology, 2014, 84, 1406-1407.	0.5	0
174	Handling patients with growing small renal masses. Canadian Urological Association Journal, 2014, 8, 28.	0.3	0
175	Editorial Comment. Urology, 2014, 83, 849-850.	0.5	0
176	Editorial Comment. Urology, 2015, 85, 1422-1423.	0.5	0
177	Reply. Urology, 2015, 85, 603-604.	0.5	0
178	Editorial Comment. Urology, 2016, 93, 129.	0.5	0
179	Editorial Comment. Journal of Urology, 2017, 198, 35-35.	0.2	0
180	Editorial Comment. Journal of Urology, 2018, 199, 400-400.	0.2	0

#	ARTICLE	IF	CITATIONS
181	Editorial Comment. Journal of Urology, 2018, 199, 59-59.	0.2	0
182	Primary Renal Well-differentiated Neuroendocrine Tumor Extending Into the Inferior Vena Cava. Urology, 2020, 135, e2-e4.	0.5	0
183	Predictors of long-term renal function after kidney surgery for patients with preoperative chronic kidney disease. Canadian Urological Association Journal, 2020, 15, E103-E109.	0.3	0
184	EDITORIAL COMMENT. Urology, 2020, 136, 167-168.	0.5	0
185	EDITORIAL COMMENT. Urology, 2021, 148, 190.	0.5	0
186	Therapy-relevant gene signatures in the high risk localized renal cell carcinoma setting: Transcriptomic data from patients receiving placebo on a randomized phase III trial (PROTECT).. Journal of Clinical Oncology, 2021, 39, 353-353.	0.8	0
187	Open partial nephrectomy with kidney split: Effective surgical approach to resect completely endophytic tumors. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 371.e1-371.e5.	0.8	0
188	Functional and Oncological Outcomes of Renal Surgery for Hilar Tumors: Informing the Decisions in Risk-Adapted Management. Urology, 2021, , .	0.5	0
189	Integrated analysis of metastatic disease in clear cell renal cell carcinoma: A collaborative TCGA analysis.. Journal of Clinical Oncology, 2014, 32, 432-432.	0.8	0
190	Neutrophil-lymphocyte ratio in small renal masses.. Journal of Clinical Oncology, 2014, 32, 522-522.	0.8	0
191	Association of baseline health and gender with small renal mass pathology.. Journal of Clinical Oncology, 2014, 32, 515-515.	0.8	0
192	Proteomic stratification of clear cell renal cell carcinoma utilizing The Cancer Genome Atlas (TCGA) with external validation.. Journal of Clinical Oncology, 2015, 33, 406-406.	0.8	0
193	The immune landscape of renal cell carcinoma and its association with intratumoral clonality.. Journal of Clinical Oncology, 2016, 34, 605-605.	0.8	0
194	Comparing surgical tissue versus biopsy tissue in the development of a clear cell renal cell carcinoma xenograft model.. Journal of Clinical Oncology, 2016, 34, 519-519.	0.8	0
195	Single-institutional analysis of patients with clear-cell papillary renal cell carcinoma.. Journal of Clinical Oncology, 2016, 34, 512-512.	0.8	0
196	Editorial Comment. Journal of Urology, 2019, 201, 708-708.	0.2	0
197	Editorial Comment. Journal of Urology, 2019, 202, 1125-1126.	0.2	0
198	Editorial Comment. Journal of Urology, 2020, 204, 441-441.	0.2	0